Merck Sharp & Dohme Corp Patent Portfolio Statistics

tip_user1

Merck Sharp & Dohme Corp.

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Merck Sharp & Dohme Corp. look like?

Assignee Art Units
Total Applications: 4,299 1,771,069
Granted Patents: 3,192 903,761
Grant Index 78.68% ↑ 65.37%
Abandoned/Rejected Applications: 865 (21.32%) 478,799 (34.63%)
In-Process Applications: 229 388,509
Average Grant Time: 2.55 Years ↓ 2.81 Years
Average Office Actions: 1.38 ↓ 1.74

Which Technology Area Merck Sharp & Dohme Corp. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1624 Organic Chemistry 699
1625 Organic Chemistry 647
1626 Organic Chemistry 488
1646 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 161
1622 Organic Chemistry 124

How many patents are Merck Sharp & Dohme Corp. filing every year?

Year Total Applications Predicted
2022 0* 443
2021 107* 297
2020 104 324
2019 121 121
2018 158 –
2017 207 –
2016 181 –
2015 203 –
2014 216 –
2013 178 –

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Merck Sharp & Dohme Corp. in USPTO?

Publication number: US20220105169A1
Application number: 17/554,354

Abstract:
The present invention provides polysaccharide-protein conjugate vaccine formulations comprising a buffer, surfactant, sugar, alkali or alkaline salt, aluminum adjuvant, optionally a bulking agent, and optionally a polymer.

Publication date: 2022-04-07
Applicant: Merck Sharp & Dohme Corp.
Inventors: Chintala Ramesh V

Publication number: US20220235041A1
Application number: 17/619,338

Abstract:
Disclosed are dihydroisoxazole compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. Also disclosed are compositions which comprise at least one of these dihydroisoxazole compounds, methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of these dihydroisoxazole compounds and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.



Publication date: –
Applicant: Merck Sharp & Dohme Corp.
Inventors: Brendan Crowley M

Publication number: None
Application number: 17/618,641

Abstract:
–

Publication date: –
Applicant: Merck Sharp & Dohme Corp.
Inventors: Luke Schenck

How are Merck Sharp & Dohme Corp.’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/554,354 Pneumococcal Conjugate Vaccine Formulations Docketed New Case – Ready for Examination OPAP Central, Docket
17/619,338 Compounds And Methods Of Use Thereof As Antibacterial Agents Docketed New Case – Ready for Examination OPAP Central, Docket
17/618,641 Containment System For Mixing Dry Powders With Solvents During Drug Production Or Processing Docketed New Case – Ready for Examination OPAP Central, Docket
17/618,687 Process For The Preparation Of 2-Fluoroadenine Docketed New Case – Ready for Examination OPAP Central, Docket
17/618,751 P53 Activator Peptidomimetic Macrocycles Docketed New Case – Ready for Examination OPAP Central, Docket